
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1651866/publications.pdf Version: 2024-02-01



LUICI RADTALENA

#	Article	IF	CITATIONS
1	Management of Graves' hyperthyroidism: present and future. Expert Review of Endocrinology and Metabolism, 2022, 17, 153-166.	1.2	19
2	Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?. Journal of Endocrinological Investigation, 2022, 45, 1455-1457.	1.8	22
3	Current concepts regarding Graves' orbitopathy. Journal of Internal Medicine, 2022, 292, 692-716.	2.7	37
4	Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace―and "titration regimes in frequency of euthyroidism and Graves' orbitopathy during treatment. Journal of Endocrinological Investigation, 2021, 44, 371-378.	n― 1.8	8
5	Change in newly diagnosed Graves' disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression. Journal of Endocrinological Investigation, 2021, 44, 1707-1718.	1.8	24
6	The Virgin Mary with a small goiter breastfeeding the Child. Journal of Endocrinological Investigation, 2021, 44, 641-642.	1.8	2
7	A young lady with goiter by Mario Sironi (1885–1961). Journal of Endocrinological Investigation, 2021, 44, 207-208.	1.8	2
8	Comics' representation of Graves' orbitopathy, by Emil Ferris. Journal of Endocrinological Investigation, 2021, 44, 1799-1800.	1.8	0
9	The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. European Journal of Endocrinology, 2021, 185, G43-G67.	1.9	362
10	Identification of Two Different Phenotypes of Patients with Amiodarone-Induced Thyrotoxicosis and Positive Thyrotropin Receptor Antibody Tests. Thyroid, 2021, 31, 1463-1471.	2.4	4
11	Statins for Graves' orbitopathy: a new tool for prevention and treatment?. Lancet Diabetes and Endocrinology,the, 2021, 9, 726-727.	5.5	2
12	Response to comment by Smith on the 2021 EUGOGO guidelines. European Journal of Endocrinology, 2021, 185, L15-L16.	1.9	1
13	Pituitary disorders as wonders and curiosity in XVI Century. Journal of Endocrinological Investigation, 2020, 43, 551-552.	1.8	0
14	Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review. Journal of Endocrinological Investigation, 2020, 43, 413-429.	1.8	26
15	Oral steroid prophylaxis for Graves' orbitopathy after radioactive iodine treatment for Graves' disease is not only effective, but also safe. Journal of Endocrinological Investigation, 2020, 43, 381-383.	1.8	12
16	Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 242-251.	1.8	36
17	Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study. Journal of Endocrinological Investigation, 2020, 43, 109-116.	1.8	18
18	A thyroid nodule in a young Sicilian princess in 1900. Journal of Endocrinological Investigation, 2020, 43, 699-700.	1.8	4

#	Article	IF	CITATIONS
19	Cushing syndrome at the court of the infant of Spain in the eighteenth century?. Journal of Endocrinological Investigation, 2020, 43, 871-872.	1.8	0
20	Treatment of Graves' hyperthyroidism with thionamides: a position paper on indications and safety in pregnancy. Journal of Endocrinological Investigation, 2020, 43, 257-265.	1.8	15
21	The multinodular goiter of the virtuous Roman matron Lucretia by Artemisia Gentileschi. Journal of Endocrinological Investigation, 2020, 43, 701-702.	1.8	2
22	Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Graves' Orbitopathy. European Thyroid Journal, 2020, 9, 3-16.	1.2	23
23	Immunological Drivers in Graves' Disease: NK Cells as a Master Switcher. Frontiers in Endocrinology, 2020, 11, 406.	1.5	23
24	Duration of Exposure to Thyrotoxicosis Increases Mortality of Compromised AIT Patients: the Role of Early Thyroidectomy. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3427-e3436.	1.8	13
25	Epidemiology, Natural History, Risk Factors, and Prevention of Graves' Orbitopathy. Frontiers in Endocrinology, 2020, 11, 615993.	1.5	132
26	Methimazole Treatment and Acute Pancreatitis: Both Caution and Reassurance Are Needed. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4967-e4969.	1.8	7
27	The interplay between thyroid and liver: implications for clinical practice. Journal of Endocrinological Investigation, 2020, 43, 885-899.	1.8	71
28	The artist's wife with a simple nontoxic goiter. Journal of Endocrinological Investigation, 2020, 43, 1043-1044.	1.8	3
29	Asymmetry indicates more severe and active disease in Graves' orbitopathy: results from a prospective cross-sectional multicentre study. Journal of Endocrinological Investigation, 2020, 43, 1717-1722.	1.8	15
30	Treatment of moderate-to-severe and active Graves' orbitopathy: a step forward from the OPTIC study. Journal of Endocrinological Investigation, 2020, 43, 1523-1525.	1.8	5
31	Graves' orbitopathy represented as feature of a state of mind. Journal of Endocrinological Investigation, 2020, 43, 1343-1344.	1.8	2
32	Effect of high-dose intravenous glucocorticoid therapy on serum thyroid hormone concentrations in type 2 amiodarone-induced thyrotoxicosis: an exploratory study. Journal of Endocrinological Investigation, 2020, 43, 1637-1643.	1.8	13
33	Management of Graves' hyperthyroidism and orbitopathy in time of COVID-19 pandemic. Journal of Endocrinological Investigation, 2020, 43, 1149-1151.	1.8	19
34	When primary hyperparathyroidism comes as good news. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.2	2
35	Serum Thyroid Hormone-Binding Proteins. , 2019, , 442-447.		3
36	Can a patient-tailored treatment approach for Graves' disease reduce mortality?. Lancet Diabetes and Endocrinology,the, 2019, 7, 245-246.	5.5	7

#	Article	IF	CITATIONS
37	The clinical enigma of the "Flea catcher―by Georges de La Tour: a pregnant sinner with pre-eclampsia or a hypothyroid girl?. Journal of Endocrinological Investigation, 2019, 42, 995-996.	1.8	1
38	Acromegaly in digital art. Journal of Endocrinological Investigation, 2019, 42, 1387-1388.	1.8	2
39	Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy?. Journal of Endocrinological Investigation, 2019, 42, 351-352.	1.8	6
40	Graves' Ophthalmopathy. , 2019, , 323-337.		1
41	Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?. European Journal of Endocrinology, 2019, 181, D27-D43.	1.9	19
42	lodine supplementation in women of reproductive age: a survey of clinical practice among Italian gynecologists and midwives. Journal of Endocrinological Investigation, 2019, 42, 353-355.	1.8	2
43	Happy Birthday, Journal of Endocrinological Investigation!. Journal of Endocrinological Investigation, 2018, 41, 1-1.	1.8	2
44	Management of Subclinical Hypothyroidism in Pregnancy: A Comment from the Italian Society of Endocrinology and the Italian Thyroid Association to the 2017 American Thyroid Association Guidelines—"The Italian Way― Thyroid, 2018, 28, 551-555.	2.4	24
45	Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism. European Journal of Endocrinology, 2018, 178, 635-643.	1.9	59
46	Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 287-298.	5.5	128
47	2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. European Thyroid Journal, 2018, 7, 55-66.	1.2	165
48	Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management. Journal of Endocrinological Investigation, 2018, 41, 1425-1432.	1.8	54
49	2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. European Thyroid Journal, 2018, 7, 167-186.	1.2	544
50	Graves' Orbitopathy: do not give it for granted. Endocrine, 2018, 62, 731-732.	1.1	1
51	Treatment of Graves' Disease. Endocrinology, 2018, , 489-511.	0.1	Ο
52	Smoking and the Thyroid. , 2018, , 719-722.		0
53	Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?. Journal of Endocrinological Investigation, 2017, 40, 547-553.	1.8	57
54	Physical performance in newly diagnosed hypothyroidism: a pilot study. Journal of Endocrinological Investigation, 2017, 40, 1099-1106.	1.8	14

LUIGI BARTALENA

#	Article	IF	CITATIONS
55	Selenium in the Treatment of Thyroid Diseases. European Thyroid Journal, 2017, 6, 113-114.	1.2	9
56	Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?. Journal of Endocrinological Investigation, 2017, 40, 885-887.	1.8	17
57	General Management Plan for Graves' Orbitopathy. , 2017, , 105-112.		Ο
58	Cardiometabolic healthy and unhealthy obesity: does vitamin D play a role?. Endocrine Connections, 2017, 6, 943-951.	0.8	17
59	Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement. Orphanet Journal of Rare Diseases, 2017, 12, 72.	1.2	113
60	Maria Carolina of Austria, Queen of Naples and Sicily: a possible case of Graves' orbitopathy. Journal of Endocrinological Investigation, 2017, 40, 239-240.	1.8	1
61	Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial. Journal of Endocrinological Investigation, 2017, 40, 281-287.	1.8	50
62	Macular Hole Surgery: The Healing Process of Outer Retinal Layers to Visual Acuity Recovery. European Journal of Ophthalmology, 2017, 27, 235-239.	0.7	24
63	The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. European Thyroid Journal, 2016, 5, 9-26.	1.2	738
64	The phenotype of newly diagnosed Graves' disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. Journal of Endocrinological Investigation, 2016, 39, 1445-1451.	1.8	51
65	Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association. Journal of Endocrinological Investigation, 2016, 39, 1465-1474.	1.8	36
66	Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if) Tj ETQ	q0 0 0 g rgE	3T /Qyerlock 1
67	Masked hypertension in newly diagnosed hypothyroidism: a pilot study. Journal of Endocrinological Investigation, 2016, 39, 1131-1138.	1.8	19
68	A 2013 European survey of clinical practice patterns in the management of Graves' disease. Clinical Endocrinology, 2016, 84, 115-120.	1.2	148
69	The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis. Journal of Endocrinological Investigation, 2016, 39, 585-591.	1.8	24
70	Cigarette smoking: number one enemy for Graves ophthalmopathy. Polish Archives of Internal Medicine, 2016, 126, 725-726.	0.3	15
71	Treatment of Graves' Disease. Endocrinology, 2016, , 1-24.	0.1	0
72	Treatment of Hyperthyroidism in Patients with Gravesâ \in ™ Orbitopathy. , 2015, , 213-222.		0

#	Article	IF	CITATIONS
73	Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. Journal of Endocrinological Investigation, 2015, 38, 481-487.	1.8	44
74	Eyelid myiasis caused by <i>Cordylobia anthropophaga</i> . Ocular Immunology and Inflammation, 2015, 23, 259-260.	1.0	3
75	PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. British Journal of Ophthalmology, 2015, 99, 1531-1535.	2.1	92
76	Outcome Prediction of Treatment of Graves' Hyperthyroidism with Antithyroid Drugs. Hormone and Metabolic Research, 2015, 47, 767-772.	0.7	34
77	The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. European Thyroid Journal, 2015, 4, 149-163.	1.2	225
78	Amiodaron i tarczyca. Endokrynologia Polska, 2015, 66, 176-196.	0.3	32
79	Graves'-like orbitopathy: do not forget IgG4-related disease. Journal of Endocrinological Investigation, 2014, 37, 1233-1235.	1.8	15
80	Vitreous Substitutes: The Present and the Future. BioMed Research International, 2014, 2014, 1-12.	0.9	86
81	What is the Role of Medical Therapy in the Management of Graves' Orbitopathy?. Acta Endocrinologica, 2014, 10, 249-258.	0.1	Ο
82	Steroid Prophylaxis After Radioiodine Treatment for Graves' Hyperthyroidism: Selective or Universal?. Thyroid, 2014, 24, 1441-1442.	2.4	5
83	Commentary. Ophthalmic Plastic and Reconstructive Surgery, 2014, 30, 420-423.	0.4	15
84	The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. European Journal of Endocrinology, 2014, 171, 363-368.	1.9	43
85	Pituitary apoplexy during pregnancy: a rare, but dangerous headache. Journal of Endocrinological Investigation, 2014, 37, 789-797.	1.8	29
86	Extrathyroidal manifestations of Graves' disease: a 2014 update. Journal of Endocrinological Investigation, 2014, 37, 691-700.	1.8	198
87	Effects of Amiodarone, Thyroid Hormones and CYP2C9 and VKORC1 Polymorphisms on Warfarin Metabolism: A Review of the Literature. Endocrine Practice, 2013, 19, 1043-1049.	1.1	16
88	Diagnosis and management of Graves disease: a global overview. Nature Reviews Endocrinology, 2013, 9, 724-734.	4.3	215
89	Graves' Orbitopathy: Imperfect Treatments for a Rare Disease. European Thyroid Journal, 2013, 2, 259-269.	1.2	57
90	A teleconsultation network improves the efficacy of anti-VEGF therapy in retinal diseases. Journal of Telemedicine and Telecare, 2013, 19, 437-442.	1.4	16

#	Article	IF	CITATIONS
91	Prevalence and Natural History of Graves' Orbitopathy in a Large Series of Patients With Newly Diagnosed Graves' Hyperthyroidism Seen at a Single Center. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1443-1449.	1.8	253
92	Prevalence and natural history of Graves' orbitopathy in the XXI century. Journal of Endocrinological Investigation, 2013, 36, 444-9.	1.8	70
93	Role of oxidative stress and selenium in Graves' hyperthyroidism and orbitopathy. Journal of Endocrinological Investigation, 2013, 36, 15-20.	1.8	14
94	Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association. European Journal of Endocrinology, 2012, 166, 247-253.	1.9	112
95	Total Thyroidectomy in Patients with Amiodarone-Induced Thyrotoxicosis and Severe Left Ventricular Systolic Dysfunction. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3515-3521.	1.8	58
96	Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4454-4463.	1.8	282
97	Prevention of Graves' ophthalmopathy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 371-379.	2.2	67
98	Amiodaroneâ€induced thyrotoxicosis, an overview of <scp>UK</scp> management. Clinical Endocrinology, 2012, 77, 936-937.	1.2	8
99	Efficacy and Safety of Orbital Radiotherapy for Graves' Orbitopathy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3857-3865.	1.8	87
100	Treating Graves' orbitopathy: where are we?. Endocrine, 2012, 41, 167-168.	1.1	5
101	Amiodarone and the thyroid: a 2012 update. Journal of Endocrinological Investigation, 2012, 35, 340-8.	1.8	66
102	Nodule size and fine-needle aspiration biopsy: diagnostic challenges for thyroid malignancy. American Journal of Surgery, 2011, 201, 525-530.	0.9	12
103	Selenium and the Course of Mild Graves' Orbitopathy. New England Journal of Medicine, 2011, 364, 1920-1931.	13.9	503
104	Continuation of Amiodarone Delays Restoration of Euthyroidism in Patients with Type 2 Amiodarone-Induced Thyrotoxicosis Treated with Prednisone: A Pilot Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3374-3380.	1.8	49
105	The Dilemma of How to Manage Graves' Hyperthyroidism in Patients with Associated Orbitopathy. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 592-599.	1.8	94
106	The American Thyroid Association/American Association of Clinical Endocrinologists Guidelines for Hyperthyroidism and Other Causes of Thyrotoxicosis: A European Perspective. Thyroid, 2011, 21, 585-591.	2.4	74
107	What to do for moderateâ€ŧoâ€severe and active Graves' orbitopathy if glucocorticoids fail?. Clinical Endocrinology, 2010, 73, 149-152.	1.2	22
108	Approach to the Patient with Amiodarone-Induced Thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2529-2535.	1.8	166

#	Article	IF	CITATIONS
109	The Challenge of Orbital Decompression in a Patient with Multiple Autoimmune Diseases and Graves' Orbitopathy: A Case Report and Review of Literature. Orbit, 2010, 29, 48-50.	0.5	0
110	Lower Dose Prednisone Prevents Radioiodine-Associated Exacerbation of Initially Mild or Absent Graves' Orbitopathy: A Retrospective Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1333-1337.	1.8	117
111	Impact of Lithium on Efficacy of Radioactive Iodine Therapy for Graves' Disease: A Cohort Study on Cure Rate, Time to Cure, and Frequency of Increased Serum Thyroxine After Antithyroid Drug Withdrawal. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 201-208.	1.8	75
112	Analysis of voice in patients with untreated active acromegaly. Journal of Endocrinological Investigation, 2010, 33, 178-185.	1.8	10
113	Glucocorticoid administration for Graves' hyperthyroidism treated by radioiodine. A questionnaire survey among members of the European Thyroid Association. Journal of Endocrinological Investigation, 2010, 33, 409-413.	1.8	13
114	Novel treatment modalities for Graves' orbitopathy. Pediatric Endocrinology Reviews, 2010, 7 Suppl 2, 210-6.	1.2	1
115	Glucocorticoids Are Preferable to Thionamides as First-Line Treatment for Amiodarone-Induced Thyrotoxicosis due to Destructive Thyroiditis: A Matched Retrospective Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3757-3762.	1.8	51
116	Thyroid Autoimmunity and Environment. Hormone and Metabolic Research, 2009, 41, 436-442.	0.7	50
117	Plasma total and acylated Ghrelin concentrations in patients with clinical and subclinical thyroid dysfunction. Journal of Endocrinological Investigation, 2009, 32, 74-78.	1.8	18
118	Reduced colonic apoptosis in mice overexpressing bovine growth hormone occurs through changes in several kinase pathways. Growth Hormone and IGF Research, 2009, 19, 432-441.	0.5	5
119	Time interval in diagnosis and treatment of papillary thyroid cancer: a descriptive, retrospective study. American Journal of Surgery, 2009, 197, 434-438.	0.9	5
120	Graves' Ophthalmopathy. New England Journal of Medicine, 2009, 360, 994-1001.	13.9	287
121	Changes in the expression of suppressor of cytokine signalling (SOCS) 2 in the colonic mucosa of acromegalic patients are associated with hyperplastic polyps. Clinical Endocrinology, 2009, 70, 898-906.	1.2	9
122	Thyroid Hormone Treatment for Differentiated Thyroid Carcinoma: What Drug, How Long, What Dose?. Current Cancer Therapy Reviews, 2009, 5, 296-302.	0.2	0
123	Diagnosis and management of amiodaroneâ€induced thyrotoxicosis: similarities and differences between North American and European thyroidologists*. Clinical Endocrinology, 2008, 69, 812-818.	1.2	75
124	Relation between Graves' orbitopathy and radioiodine therapy for hyperthyroidism: facts and unsolved questions*. Clinical Endocrinology, 2008, 69, 845-847.	1.2	21
125	Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. European Journal of Endocrinology, 2008, 158, 273-285.	1.9	611
126	Declaración de consenso del Grupo europeo sobre la orbitopatÃa de Graves (EUGOGO) sobre el tratamiento de la orbitopatÃa de Graves (OG). Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2008, 55, 356.e1-356.e13.	0.8	0

#	Article	IF	CITATIONS
127	Shortening hospital stay for thyroid surgery. Expert Review of Medical Devices, 2008, 5, 85-96.	1.4	3
128	Potassium perchlorate only temporarily restores euthyroidism in patients with amiodarone-induced hypothyroidism who continue amiodarone therapy. Journal of Endocrinological Investigation, 2008, 31, 515-519.	1.8	14
129	Graves' hyperthyroidism of recent onset and Graves' orbitopathy: To ablate or not to ablate the thyroid?. Journal of Endocrinological Investigation, 2008, 31, 578-581.	1.8	12
130	Identification, treatment and management of cardiovascular risks in patients with acromegaly. Expert Review of Endocrinology and Metabolism, 2008, 3, 603-614.	1.2	1
131	Amiodarone-induced thyrotoxicosis: something new to refine the initial diagnosis?. European Journal of Endocrinology, 2008, 159, 359-361.	1.9	25
132	Perspectives in pharmacological management of Graves' hyperthyroidism and orbitopathy. Expert Review of Clinical Immunology, 2008, 4, 321-329.	1.3	0
133	Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy. Thyroid, 2008, 18, 333-346.	2.4	342
134	Novel Immunomodulating Agents for Graves Orbitopathy. Ophthalmic Plastic and Reconstructive Surgery, 2008, 24, 251-256.	0.4	24
135	Hyperthyroidism Due to Graves‗ Disease – Is There an Optimal Pharmacological Treatment Regimen?. European Endocrinology, 2008, 4, 63.	0.8	Ο
136	Medullary thyroid carcinoma: surgical treatment advances. Expert Review of Anticancer Therapy, 2007, 7, 877-885.	1.1	15
137	Effects of Total Thyroid Ablation Versus Near-Total Thyroidectomy Alone on Mild to Moderate Graves' Orbitopathy Treated with Intravenous Glucocorticoids. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1653-1658.	1.8	121
138	Cardiac expression of adenine nucleotide translocase-1 in transgenic mice overexpressing bovine GH. Journal of Endocrinology, 2007, 194, 521-527.	1.2	7
139	Glucocorticoid Response in Amiodarone-Induced Thyrotoxicosis Resulting from Destructive Thyroiditis Is Predicted by Thyroid Volume and Serum Free Thyroid Hormone Concentrations. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 556-562.	1.8	70
140	Prevalence and Functional Significance of Antipituitary Antibodies in Patients with Autoimmune and Non-Autoimmune Thyroid Diseases. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2176-2181.	1.8	74
141	Changes in Autonomic Modulation to the Heart and Intracellular Catecholamines. Hormone Research in Paediatrics, 2007, 67, 171-178.	0.8	6
142	Pain Perception, Blood Pressure Levels, and Peripheral Benzodiazepine Receptors in Patients Followed for Differentiated Thyroid Carcinoma: A Longitudinal Study in Hypothyroidism and During Hormone Treatment. Clinical Journal of Pain, 2007, 23, 518-523.	0.8	7
143	Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. Clinical Endocrinology, 2007, 67, 070611013542001-???.	1.2	47
144	Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study. Thrombosis and Haemostasis, 2007, 97, 803-6.	1.8	13

#	Article	IF	CITATIONS
145	Currently available somatostatin analogs are not good for Graves' orbitopathy. Journal of Endocrinological Investigation, 2006, 29, 389-390.	1.8	6
146	Long-term outcome of thyroid function after amiodarone-induced thyrotoxicosis, as compared to subacute thyroiditis. Journal of Endocrinological Investigation, 2006, 29, 694-699.	1.8	45
147	Uptake of amiodarone by thyroidal and non-thyroidal cell lines. Journal of Endocrinological Investigation, 2006, 29, 61-66.	1.8	8
148	Immunotherapy for Graves' orbitopathy: Easy enthusiasm, but let's keep trying. Journal of Endocrinological Investigation, 2006, 29, 1012-1016.	1.8	6
149	Thyroid hormone regulation of cell migration and oxidative metabolism in polymorphonuclear leukocytes: Clinical evidence in thyroidectomized subjects on thyroxine replacement therapy. Life Sciences, 2006, 78, 1071-1077.	2.0	24
150	Management of amiodarone-induced thyrotoxicosis in Latin America: an electronic survey. Clinical Endocrinology, 2006, 65, 433-438.	1.2	33
151	Abnormal expression of PPAR gamma isoforms in the subcutaneous adipose tissue of patients with Cushing's disease. Clinical Endocrinology, 2006, 66, 060904075417002-???.	1.2	2
152	Identification of Acromegalic Patients at Risk of Developing Colonic Adenomas. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1351-1356.	1.8	48
153	The reduction of bone mineral density in postmenopausal women with primary hyperparathyroidism is higher in the presence of concomitant GH secretion impairment. European Journal of Endocrinology, 2006, 155, 41-45.	1.9	2
154	Thyroid Color Flow Doppler Sonography: An Adjunctive Tool for Differentiating Patients with Inappropriate Thyrotropin (TSH) Secretion Due to TSH-Secreting Pituitary Adenoma or Resistance to Thyroid Hormone. Thyroid, 2006, 16, 989-995.	2.4	17
155	Surgery of lymph nodes in papillary thyroid cancer. Expert Review of Anticancer Therapy, 2006, 6, 1217-1229.	1.1	24
156	Apoptosis is reduced in the colonic mucosa of patients with acromegaly. Clinical Endocrinology, 2005, 63, 683-688.	1.2	22
157	Glucocorticoids and outcome of radioactive iodine therapy for Graves' hyperthyroidism. European Journal of Endocrinology, 2005, 153, 13-14.	1.9	18
158	Glucocorticoids for Graves' Ophthalmopathy: How and When1. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5497-5499.	1.8	39
159	An update on the pharmacological management of hyperthyroidism due to Graves' disease. Expert Opinion on Pharmacotherapy, 2005, 6, 851-861.	0.9	12
160	Thyroid function differently affects serum cystatin Cand creatinine concentrations. Journal of Endocrinological Investigation, 2005, 28, 346-349.	1.8	172
161	Graves' ophthalmopathy: Search for shared autoantigen(s) continues. Journal of Endocrinological Investigation, 2005, 28, 396-397.	1.8	4
162	Growth hormone secretion in primary and secondary hyperparathyroidism. Journal of Endocrinological Investigation, 2005, 28, 113-116.	1.8	8

#	Article	IF	CITATIONS
163	Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves. Journal of Endocrinological Investigation, 2005, 28, 280-284.	1.8	46
164	An update on medical management of Graves' ophthalmopathy. Journal of Endocrinological Investigation, 2005, 28, 469-478.	1.8	44
165	Somatostatin Analogs for Graves' Ophthalmopathy: Do They Bounce Off like a Rubber Bullet?. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5908-5909.	1.8	21
166	PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. European Journal of Endocrinology, 2004, 150, 863-875.	1.9	37
167	Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. Clinical Endocrinology, 2004, 61, 494-502.	1.2	78
168	Acute and Severe Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy in Patients with Graves' Ophthalmopathy. Thyroid, 2004, 14, 403-406.	2.4	151
169	La prevenzione dell'oftalmopatia basedowiana. L Endocrinologo, 2004, 5, 47-51.	0.0	0
170	Relationship between management of hyperthyroidism and course of the ophthalmopathy. Journal of Endocrinological Investigation, 2004, 27, 288-294.	1.8	41
171	Graves' ophthalmopathy: State of the art and perspectives. Journal of Endocrinological Investigation, 2004, 27, 295-301.	1.8	77
172	Mutations in the SLC26A4 (pendrin) gene in patients with sensorineural deafness and enlarged vestibular aqueduct. Journal of Endocrinological Investigation, 2004, 27, 430-435.	1.8	31
173	Serum prostate-specific antigen concentration is increased in acromegalic women. Journal of Endocrinological Investigation, 2004, 27, 643-647.	1.8	4
174	Improvement of Growth Hormone Deficiency in Patients with Primary Hyperparathyroidism after Parathyroidectomy: Results of a Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1213-1216.	1.8	10
175	Oxidative stress and Graves' ophthalmopathy: <i>In vitro</i> studies and therapeutic implications. BioFactors, 2003, 19, 155-163.	2.6	71
176	Orbital radiotherapy for Graves' ophthalmopathy: Useful or useless? Safe or dangerous?. Journal of Endocrinological Investigation, 2003, 26, 5-16.	1.8	39
177	Antithyroid drug treatment prior to radioiodine therapy for Graves' disease: Yes or no?. Journal of Endocrinological Investigation, 2003, 26, 174-176.	1.8	7
178	Colonic polyps of acromegalic patients are not associated with mutations of the peroxisome proliferator activated receptor 13 gene. Journal of Endocrinological Investigation, 2003, 26, 1054-1058.	1.8	4
179	Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. Journal of Endocrinological Investigation, 2003, 26, 635-640.	1.8	62
180	Effects of a mixture of polychlorinated biphenyls (Aroclor 1254) on the transcriptional activity of thyroid hormone receptor. Journal of Endocrinological Investigation, 2003, 26, 972-978.	1.8	45

#	Article	IF	CITATIONS
181	The dilemma of non-thyroidal illness syndrome: to treat or not to treat?. Journal of Endocrinological Investigation, 2003, 26, 1162-1162.	1.8	14
182	Treatment of Type II Amiodarone-Induced Thyrotoxicosis by Either Iopanoic Acid or Glucocorticoids: A Prospective, Randomized Study. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1999-2002.	1.8	77
183	Changes in the Expression of the Peroxisome Proliferator-Activated Receptor Î ³ Gene in the Colonic Polyps and Colonic Mucosa of Acromegalic Patients. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3938-3942.	1.8	19
184	Long-Term Safety of Orbital Radiotherapy for Graves' Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3561-3566.	1.8	105
185	The role of somatostatin analogs in the management of Graves' ophthalmopathy. Journal of Endocrinological Investigation, 2003, 26, 109-13.	1.8	3
186	Orbital Radiotherapy for Graves' Ophthalmopathy. Thyroid, 2002, 12, 245-250.	2.4	85
187	Thyroid vascularity is increased in patients with active acromegaly. Clinical Endocrinology, 2002, 57, 65-70.	1.2	16
188	Treatment with Lithium Prevents Serum Thyroid Hormone Increase after Thionamide Withdrawal and Radioiodine Therapy in Patients with Graves' Disease. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4490-4495.	1.8	69
189	GH Secretion Is Impaired in Patients with Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1961-1964.	1.8	22
190	Graves' ophthalmopathy: a preventable disease?. European Journal of Endocrinology, 2002, 146, 457-461.	1.9	69
191	Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres. European Journal of Endocrinology, 2002, 147, 1-11.	1.9	46
192	Radioiodine therapy and Graves \hat{E} ¼ ophthalmopathy. Nuclear Medicine Communications, 2002, 23, 1143-1145.	0.5	2
193	lopanoic acid rapidly controls Type I amiodarone-induced thyrotoxicosis prior to thyroidectomy. Journal of Endocrinological Investigation, 2002, 25, 176-180.	1.8	46
194	Primary hyperparathyroidism is associated with an impaired secretion of growth hormone but not of the other anterior pituitary hormones. Journal of Endocrinological Investigation, 2002, 25, RC7-RC9.	1.8	5
195	Smoking and Graves' disease. Journal of Endocrinological Investigation, 2002, 25, 402-402.	1.8	19
196	Epidemiology and Prevention of Graves' Ophthalmopathy. Thyroid, 2002, 12, 855-860.	2.4	390
197	Adjuvant Effect of Lithium on Radioiodine Treatment of Hyperthyroidism. Thyroid, 2002, 12, 1153-1154.	2.4	15
198	Management of thyroid eye disease. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, S458-S465.	3.3	23

#	Article	IF	CITATIONS
199	Amiodarone-induced thyrotoxicosis: a difficult diagnostic and therapeutic challenge*. Clinical Endocrinology, 2002, 56, 23-24.	1.2	49
200	Novel Approaches to the Management of Graves` Ophthalmopathy. Hormones, 2002, 1, 76-90.	0.9	15
201	The Various Effects of Amiodarone on Thyroid Function. Thyroid, 2001, 11, 511-519.	2.4	135
202	Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. Journal of Endocrinological Investigation, 2001, 24, 116-130.	1.8	179
203	Desethylamiodarone antagonizes the effect of thyroid hormone at the molecular level. European Journal of Endocrinology, 2001, 145, 59-64.	1.9	27
204	Comparison of the Effectiveness and Tolerability of Intravenous or Oral Glucocorticoids Associated with Orbital Radiotherapy in the Management of Severe Graves' Ophthalmopathy: Results of a Prospective, Single-Blind, Randomized Study. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3562-3567.	1.8	232
205	The Effects of Amiodarone on the Thyroid*. Endocrine Reviews, 2001, 22, 240-254.	8.9	389
206	A novel mutation in the pendrin gene associated with Pendred's syndrome. Clinical Endocrinology, 2000, 52, 279-285.	1.2	26
207	Soluble interleukin-1 receptor antagonist concentration in patients with Graves' ophthalmopathy is neither related to cigarette smoking nor predictive of subsequent response to glucocorticoids. Clinical Endocrinology, 2000, 52, 647-651.	1.2	22
208	Management of Graves' Ophthalmopathy: Reality and Perspectives*. Endocrine Reviews, 2000, 21, 168-199.	8.9	527
209	Pendrin does not increase sulfate uptake in mammalian COS-7 cells. Journal of Endocrinological Investigation, 2000, 23, 170-172.	1.8	12
210	Management of Graves' Ophthalmopathy: Reality and Perspectives. , 2000, 21, 168-199.		183
211	Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels: studies in vivo by color flow doppler sonography. European Journal of Endocrinology, 1999, 140, 452-456.	1.9	113
212	The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clinical Endocrinology, 1999, 51, 503-508.	1.2	85
213	Is thyroxine during lithium therapy necessary?. Journal of Endocrinological Investigation, 1999, 22, 220-222.	1.8	11
214	The age of patients with thyrotoxicosis factitia in Italy from 1973 to 1996. Journal of Endocrinological Investigation, 1999, 22, 128-133.	1.8	26
215	Interleukin-6 Levels are not Increased in Women with Postpartum Thyroid Dysfunction. Thyroid, 1998, 8, 371-375.	2.4	15
216	Orbital Radiotherapy for Graves' Ophthalmopathy. Thyroid, 1998, 8, 439-441.	2.4	39

#	Article	IF	CITATIONS
217	Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy. New England Journal of Medicine, 1998, 338, 73-78.	13.9	644
218	Cigarette Smoking and Treatment Outcomes in Graves Ophthalmopathy. Annals of Internal Medicine, 1998, 129, 632.	2.0	243
219	Role of cytokines in the pathogenesis of the euthyroid sick syndrome. European Journal of Endocrinology, 1998, 138, 603-614.	1.9	84
220	Color Flow Doppler Sonography Rapidly Differentiates Type I and Type II Amiodarone-Induced Thyrotoxicosis. Thyroid, 1997, 7, 541-545.	2.4	173
221	Graves' hyperthyroidism and ophthalmopathy associated with pemphigus vulgaris: Onset of thyroid autoimmune disease during chronic low-dose glucocorticoid therapy. Journal of Endocrinological Investigation, 1997, 20, 155-157.	1.8	19
222	Treating severe Graves' ophthalmopathy. Bailliere's Clinical Endocrinology and Metabolism, 1997, 11, 521-536.	1.0	80
223	l-thyroxine directly affects expression of thyroid hormone-sensitive genes: regulatory effect of RXRβ. Molecular and Cellular Endocrinology, 1997, 134, 23-31.	1.6	25
224	Adverse Effects of Thyroid Hormone Preparations and Antithyroid Drugs. Drug Safety, 1996, 15, 53-63.	1.4	88
225	Color flow doppler sonography in thyrotoxicosis factitia. Journal of Endocrinological Investigation, 1996, 19, 603-606.	1.8	49
226	Study of serum 3,5,3′-triiodothyronine sulfate concentration in patients with systemic non-thyroidal illness. European Journal of Endocrinology, 1996, 134, 45-49.	1.9	26
227	Circulating levels of anticonvulsant metabolites of progesterone in women with partial epilepsy in the intercritical phase. Italian Journal of Neurological Sciences, 1996, 17, 277-281.	0.1	5
228	Graves' Disease Occurring after Subacute Thyroiditis: Report of a Case and Review of the Literature. Thyroid, 1996, 6, 345-348.	2.4	59
229	Radioiodine and thyroid-associated ophthalmopathy. Orbit, 1996, 15, 197-203.	0.5	5
230	Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2930-2933.	1.8	180
231	Cytokine antagonists: new ideas for the management of Graves' ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 446-448.	1.8	23
232	Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2930-2933.	1.8	160
233	Therapeutic controversies. Radioiodine may be bad for Graves' ophthalmopathy, but Journal of Clinical Endocrinology and Metabolism, 1995, 80, 342-345.	1.8	27
234	Cigarette smoking and the thyroid. European Journal of Endocrinology, 1995, 133, 507-512.	1.9	108

#	Article	IF	CITATIONS
235	Circadian thyrotropin variations are preserved in normal pregnant women. European Journal of Endocrinology, 1995, 133, 71-74.	1.9	7
236	Percutaneous ethanol injection: what is its role in the management of nodular lesions of endocrine glands?. European Journal of Endocrinology, 1995, 132, 300-301.	1.9	6
237	Interleukin-6 and the thyroid. European Journal of Endocrinology, 1995, 132, 386-393.	1.9	37
238	Non-autoimmune hyperthyroidism associated with isolated bilateral ocular lymphoma mimicking Graves' disease with ophthalmopathy: A cause of misdiagnosis. Journal of Endocrinological Investigation, 1995, 18, 817-819.	1.8	9
239	Interleukin 6 effects on the pituitary–thyroid axis in the rat. European Journal of Endocrinology, 1994, 131, 302-306.	1.9	26
240	Serum interleukin-6 in amiodarone-induced thyrotoxicosis Journal of Clinical Endocrinology and Metabolism, 1994, 78, 423-427.	1.8	129
241	Interleukin-6: a marker of thyroid-destructive processes?. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 1424-1427.	1.8	64
242	Diagnosis of thyroid dysfunction: present and future. Nuclear Medicine and Biology, 1994, 21, 531-544.	0.3	1
243	Relationship of the increased serum interleukin-6 concentration to changes of thyroid function in nonthyroidal illness. Journal of Endocrinological Investigation, 1994, 17, 269-274.	1.8	84
244	Levothyroxine suppressive therapy: Harmful and useless or harmless and useful?. Journal of Endocrinological Investigation, 1994, 17, 675-677.	1.8	15
245	Serum interleukin-6 in amiodarone-induced thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 423-427.	1.8	103
246	Effects of thyroxine excess on peripheral organs. Vienna Clinical Weekly, 1994, 21, 60-5.	0.9	8
247	Increased serum interleukin-6 concentration in patients with subacute thyroiditis: relationship with concomitant changes in serum T4-binding globulin concentration. Journal of Endocrinological Investigation, 1993, 16, 213-218.	1.8	59
248	Studies on thyroxine-binding globulin. Journal of Endocrinological Investigation, 1993, 16, 353-371.	1.8	8
249	Octreotide treatment does not affect the size of most nonfunctioning pituitary adenomas. Journal of Endocrinological Investigation, 1993, 16, 541-543.	1.8	31
250	Relationship between nocturnal serum thyrotropin peak and metabolic control in diabetic patients. Journal of Clinical Endocrinology and Metabolism, 1993, 76, 983-987.	1.8	17
251	Thyroid hormone transport proteins. Clinics in Laboratory Medicine, 1993, 13, 583-98.	0.7	27
252	Variations in Thyroid Hormone Transport Proteins and Their Clinical Implications. Thyroid, 1992, 2, 237-245.	2.4	81

#	Article	IF	CITATIONS
253	Effects of interleukin-6 on the expression of thyroid hormone-binding protein genes in cultured human hepatoblastoma-derived (Hep G2) cells. Molecular Endocrinology, 1992, 6, 935-942.	3.7	23
254	Relationship Between Graves' Ophthalmopathy and Type of Treatment of Graves' Hyperthyroidism. Thyroid, 1992, 2, 171-178.	2.4	81
255	lodine contamination in subjects admitted to a general hospital. Journal of Endocrinological Investigation, 1992, 15, 307-308.	1.8	5
256	Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism. Journal of Endocrinological Investigation, 1991, 14, 847-851.	1.8	26
257	Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. Journal of Endocrinological Investigation, 1991, 14, 853-860.	1.8	149
258	The Lack of Nocturnal Serum Thyrotropin Surge in Patients with Nontoxic Nodular Goiter May Predict the Subsequent Occurrence of Hyperthyroidism*. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 604-608.	1.8	17
259	The Nocturnal Serum Thyrotropin Surge is Abolished in Patients with Adrenocorticotropin (ACTH)-Dependent or ACTH-Independent Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 1195-1199.	1.8	58
260	Thyroid function tests and diagnostic protocols for investigation of thyroid dysfunction. Annali Dell'Istituto Superiore Di Sanita, 1991, 27, 531-9.	0.2	1
261	Recent Achievements in Studies on Thyroid Hormone-Binding Proteins*. Endocrine Reviews, 1990, 11, 47-64.	8.9	117
262	Lack of Nocturnal Serum Thyrotropin Surge after Surgery*. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 293-296.	1.8	52
263	Nocturnal Serum Thyrotropin (TSH) Surge and the TSH Response to TSH-Releasing Hormone: Dissociated Behavior in Untreated Depressives*. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 650-655.	1.8	72
264	The differentiation-inducing agent sodium butyrate produces divergent effects on albumin and thyroxine-binding globulin synthesis by human hepatoblastoma-derived (Hep G2) cells. Journal of Endocrinological Investigation, 1990, 13, 917-922.	1.8	8
265	Neuropsychological assessment in schoolchildren from an area of moderate iodine deficiency. Journal of Endocrinological Investigation, 1990, 13, 427-431.	1.8	59
266	Evaluation of thyroid function in patients with rapid-cycling and non-rapid-cycling bipolar disorder. Psychiatry Research, 1990, 34, 13-17.	1.7	52
267	Lack of nocturnal serum thyrotropin (TSH) surge in patients with chronic renal failure undergoing regular maintenance hemofiltration: a case of central hypothyroidism. Clinical Nephrology, 1990, 34, 30-4.	0.4	7
268	Studies on the occurrence of ophthalmopathy in Graves' disease. European Journal of Endocrinology, 1989, 120, 473-478.	1.9	127
269	Use of Corticosteroids to Prevent Progression of Graves' Ophthalmopathy after Radioiodine Therapy for Hyperthyroidism. New England Journal of Medicine, 1989, 321, 1349-1352.	13.9	296
270	More on smoking habits and Graves' ophthalmopathy. Journal of Endocrinological Investigation, 1989, 12, 733-737.	1.8	187

#	Article	IF	CITATIONS
271	Effects of the antileukemic drug L-asparaginase on sex hormone-binding globulin: studies in vivo and in vitro. Journal of Endocrinological Investigation, 1989, 12, 489-493.	1.8	1
272	Ontogeny of Pancreatic TRH Occurs Independently of Brain Development Annals of the New York Academy of Sciences, 1989, 553, 624-625.	1.8	0
273	Orbital decompression for severe Graves' ophthalmopathy. Results of a three-wall operative technique. Journal of Neurosurgical Sciences, 1989, 33, 323-7.	0.3	6
274	The effect of altered thyroid function on serum fructosamine concentrations. Clinical Biochemistry, 1988, 21, 179-181.	0.8	12
275	Absence of serum thyroid hormone autoantibodies in patients chronically treated with amiodarone. Journal of Endocrinological Investigation, 1988, 11, 323-325.	1.8	9
276	Free thyroxine values in dried blood spots on filter paper in newborns are related to both gestational age and birth body weight. Journal of Endocrinological Investigation, 1988, 11, 515-519.	1.8	4
277	Thyroxine uptake by human hepatoma cells from serum of patients submitted to long-term thyroxine suppressive therapy. Journal of Endocrinological Investigation, 1988, 11, 629-635.	1.8	1
278	Radioactive iodine thyroid uptake in patients with amiodarone-iodine-induced thyroid dysfunction. European Journal of Endocrinology, 1988, 119, 167-173.	1.9	57
279	Free Thyroxine and Free Triiodothyronine Measurement in Dried Blood Spots on Filter Paper by Column Adsorption Chromatography Followed by Radioimmunoassay. Hormone and Metabolic Research, 1988, 20, 293-297.	0.7	6
280	Factors Affecting Suppression of Endogenous Thyrotropin Secretion by Thyroxine Treatment: Retrospective Analysis in Athyreotic and Goitrous Patients*. Journal of Clinical Endocrinology and Metabolism, 1987, 64, 849-855.	1.8	68
281	Evaluation of the Nocturnal Serum Thyrotropin (TSH) Surge, as Assessed by TSH Ultrasensitive Assay, in Patients Receiving Long Term <scp>I</scp> -Thyroxine Suppression Therapy and in Patients with Various Thyroid Disorders*. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 1265-1271.	1.8	48
282	Interaction of the thyrotropin receptor on rat FRTL-5 thyroid cells with thyrotropin and a thyrotropin-stimulating autoantibody from Graves' patients. Biochemical and Biophysical Research Communications, 1987, 143, 266-272.	1.0	7
283	Diagnosis of amiodarone-iodine-induced thyrotoxicosis(AIIT) associated with severe nonthyroidal illness. Journal of Endocrinological Investigation, 1987, 10, 589-591.	1.8	17
284	High prevalence of subacute thyroiditis during summer season in Italy. Journal of Endocrinological Investigation, 1987, 10, 321-323.	1.8	87
285	Serum TSH measurements by a sensitive enzyme immunoassay discriminate euthyroid from hyperthyroid subjects and avoid the need for TRH test during suppressive therapy with L-thyroxine. Clinical Biochemistry, 1987, 20, 197-200.	0.8	4
286	AMIODARONE IODINEâ€INDUCED HYPOTHYROIDISM: RISK FACTORS AND FOLLOWâ€UP IN 28 CASES. Clinical Endocrinology, 1987, 26, 227-237.	1.2	108
287	ORBITAL COBALT IRRADIATION COMBINED WITH RETROBULBAR OR SYSTEMIC CORTICOSTEROIDS FOR GRAVES' OPHTHALMOPATHY: A COMPARATIVE STUDY. Clinical Endocrinology, 1987, 27, 33-42.	1.2	122
288	Serum free thyroid hormones in subclinical hypothyroidism. Journal of Endocrinological Investigation, 1986, 9, 315-319.	1.8	9

#	Article	IF	CITATIONS
289	Role of autoimmune and familial factors in goiter prevalence. Studies performed in a moderately endemic area. Journal of Endocrinological Investigation, 1986, 9, 161-164.	1.8	30
290	Serum thyrotropin by ultrasensitive immunoradiometric assay and serum free thyroid hormones in pregnancy. Journal of Endocrinological Investigation, 1986, 9, 185-189.	1.8	35
291	HUMAN SERUM THYROTROPHIN MEASUREMENT BY ULTRASENSITIVE IMMUNORADIOMETRIC ASSAY AS A FIRSTâ€LINE TEST IN THE EVALUATION OF THYROID FUNCTION. Clinical Endocrinology, 1986, 24, 141-148.	1.2	60
292	Changes in Radioimmunoassayable Prealbumin (TBPA) Serum Levels from Birth to Adulthood. Hormone and Metabolic Research, 1986, 18, 73-73.	0.7	7
293	Serum thyroid hormones and thyroid hormone binding proteins in patients with completed stroke. Annals of Clinical Research, 1986, 18, 203-7.	0.2	1
294	Thyroid autoimmunity and endemic goiter. Endocrinologia Experimentalis, 1986, 20, 49-56.	0.0	5
295	RECIPROCAL CHANGES OF SERUM THYROGLOBULIN AND TSH IN RESIDENTS OF A MODERATE ENDEMIC GOITRE AREA. Clinical Endocrinology, 1985, 23, 115-122.	1.2	56
296	Characterization of nascent and secreted thyroxine-binding globulin in cultured human hepatoma (Hep G2) cells. Journal of Biological Chemistry, 1984, 259, 13605-9.	1.6	16
297	Effect of tunicamycin and monensin on secretion of thyroxine-binding globulin by cultured human hepatoma (Hep G2) cells. Journal of Biological Chemistry, 1984, 259, 13610-4.	1.6	20
298	TSH-displacing activity versus TSH-binding inhibiting activity of immunoglobulins from patients with Graves' disease. Journal of Endocrinological Investigation, 1983, 6, 375-378.	1.8	5
299	Orbital Cobalt Irradiation Combined with Systemic Corticosteroids for Graves' Ophthalmopathy: Comparison with Systemic Corticosteroids Alone*. Journal of Clinical Endocrinology and Metabolism, 1983, 56, 1139-1144.	1.8	282
300	Polymorphism of Human Thyroxine-Binding Globulin. Journal of Clinical Endocrinology and Metabolism, 1983, 57, 1186-1192.	1.8	31
301	Studies on thyroid cell surface antigens using cultured human thyroid cells. Clinical and Experimental Immunology, 1982, 47, 336-44.	1.1	20
302	Measurement of thyroid cell surface antibodies by radioassay using human cultured thyroid cells. Journal of Endocrinological Investigation, 1981, 4, 439-444.	1.8	9
303	COMPARISON BETWEEN THYROID STIMULATING AND TSHâ€BINDING INHIBITING IMMUNOGLOBULINS OF GRAVES' DISEASE. Clinical Endocrinology, 1981, 15, 175-182.	1.2	74
304	Graves' disease and Turner's syndrome. Journal of Endocrinological Investigation, 1980, 3, 429-431.	1.8	11
305	Radio-receptor assay of TSH: its use to detect thyroid-stimulating immunoglobulins. Journal of Endocrinological Investigation, 1978, 1, 17-24.	1.8	36
306	Use of solubilized radioiodinated thyroid plasma membranes for purification of TSH-receptor by affinity chromatography. FEBS Letters, 1978, 88, 292-294.	1.3	3

#	Article	IF	CITATIONS
307	Dissociation of Responsiveness to Thyrotropin-Releasing Hormone and Thyroid Suppressibility Following Antithyroid Drug Therapy of Hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 1976, 43, 543-549.	1.8	21
308	Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity. Journal of Endocrinological Investigation, 0, , .	1.8	4
309	Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves' Disease Hyperthyroidism During Methimazole Treatment. Frontiers in Endocrinology, 0, 13, .	1.5	17